Mesothelial markers in high-grade breast carcinoma

Histopathology

Volumn 59, Issue 5, 2011, Pages 957-964

  Duhig, Edwina E ^a   Kalpakos, Lydia ^a   Yang, Ian A ^b   Clarke, Belinda E ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Basal breast carcinoma; Breast; Immunohistochemistry; Mesothelial

Indexed keywords

CALRETININ; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; THROMBOMODULIN; WT1 PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER STAGING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM GRADING; TUMOR MARKERS, BIOLOGICAL;

EID: 81555209059     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04036.x     Document Type: Article

References (19)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363; 1938-1948.
2. Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma. A phenotypically distinct entity. Arch. Pathol. Lab. Med. 2010; 134; 130-133.
3. Tsuda H, Takarabe T, Hasegawa F et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 2000; 24; 197-202.
4. Hicks DG, Short SM, Prescott NL et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin 5/6, and over express HER 2 or EGFR. Am. J. Surg. Pathol. 2006; 30; 1097-1104.
5. Van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2006; 161; 1991-1996.
6. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9; R4. (doi:10.1186/bcr1636).
7. Fernandes RCM, Bevilacqua JLB, Soares IC et al. Coordinated expression of ER, PR and HER2 define different prognostic subtypes amongst poorly differentiated breast carcinomas. Histopathology 2009; 55; 346-352.
8. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
9. Doglioni C, Tos AP, Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20; 1037-1046.
10. Cury PM, Butcher DN, Fisher C et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD 44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma of metastatic to the pleura. Mod. Pathol. 2000; 13; 107-112.
11. Passebosc-Faure K, Li G, Lambert C et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin. Cancer Res. 2005; 11; 6862-6867.
12. Kumar-Singh S, Segers K, Rodeck U et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J. Pathol. 1997; 181; 67-74.
13. Ordonez NG. Value of thyroid transcription factor-1, e-cadherin, BG8, WT1 and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 2000; 24; 598-606.
14. Armes JE, Bowlay G, Lourie R et al. Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma colon and immunohistochemical approach. Pathology 2010; 42; 534-539.
15. Miyoshi Y, Ando A, Egawa C et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 2002; 8; 1167-1171.
16. Nakatsuka S-I, Oji Y, Horiuchi T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 2006; 19; 804-814.
17. Yaziji H, Battifora H, Barry TS et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod. Pathol. 2006; 19; 514-523.
18. Van Dreden P, Rousseau A, Savoure A et al. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. Blood Coagul. Fibrinolysis 2009; 20; 635-641.
19. Creaney J, Segal A, Sterrett G et al. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br. J. Cancer 2008; 98; 1562-1569.